Oncodesign Precision Medicine (FRA:ZR8) Net Interest Margin (Bank Only) %


FRA:ZR8 Oncodesign Precision Medicine SA FRA:ZR8
32 GF Score
Price €0.30
GF Value €0.26
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Oncodesign Precision Medicine Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:ZR8
32GF Score
Oncodesign Precision Medicine SA FRA:ZR8
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncodesign Precision Medicine (FRA:ZR8) Overvalued in 2026?

Based on GuruFocus' analysis, Oncodesign Precision Medicine stock appears to be overvalued. The current stock price of €0.30 is trading 16.9% above its estimated GF Value™ of €0.26. GuruFocus considers Oncodesign Precision Medicine to be Modestly Overvalued.

Key valuation signals for FRA:ZR8:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.26 vs. price of €0.30 (16.9% above fair value)
  • GF Score™: 32/100 with 1 warning sign

No single metric tells the full story. See the FRA:ZR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncodesign Precision Medicine Business Description

Other Exchanges ALOPM:France
Address 18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
32GF Score

Get the complete analysis for FRA:ZR8

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.26
GF Value